Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28564954 | 0.85 | NPC1 (0.64) | RAB9ANPC1SMN1; SMN2MAOAMGLL | |
| SCHEMBL16088310 | 0.82 | NPC1 (0.61) | RAB9ANPC1SMN1; SMN2MAOAMGLL | |
| SCHEMBL20389370 | 0.81 | NAMPT (0.76) | RAB9ANPC1NAMPTSMN1; SMN2KMT2A | |
| SCHEMBL4872967 | 0.80 | NAMPT (0.51) | RAB9ANPC1NAMPTSMN1; SMN2KMT2A | |
| SCHEMBL17997751 | 0.80 | NPC1 (0.58) | RAB9ANPC1SMN1; SMN2MAOAMGLL | |
| SCHEMBL3041603 | 0.77 | NPC1 (0.58) | RAB9ANPC1SMN1; SMN2MAOAMGLL | |
| SCHEMBL8726462 | 0.77 | NAMPT (0.70) | RAB9ANPC1NAMPTSMN1; SMN2KMT2A | |
| SCHEMBL7336549 | 0.77 | SMN1; SMN2 (0.61) | RAB9ANPC1NAMPTSMN1; SMN2KMT2A | |
| SCHEMBL11408485 | 0.77 | KMT2A (0.76) | RAB9ANPC1NAMPTSMN1; SMN2MAOA | |
| SCHEMBL7169757 | 0.76 | MAPT (0.50) | RAB9ANPC1SMN1; SMN2KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171376-A1 | Antiarthritic agents | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-09-11 | — | — | US | disclosed |
| US-6559149-B1 | Lesser side effects without compromise in their efficacy | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-05-06 | — | — | US | disclosed |
| EP-0632038-B1 | METHOTREXATE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2001-08-22 | — | — | EP | disclosed |
| EP-0632038-A1 | METHOTREXATE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 1995-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171376-A1 | Antiarthritic agents | BCOR, RCOR1, IL4 | RAB9A 2339/4885NPC1 2566/4885NAMPT 4497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.